GlassScriptPhysician profile
Tracy M Hunter
NPI 1871048256
$4,324.90
in general payments reported to CMS, 2019-2025
30 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $479 · 2023: $824 · 2024: $1,218 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $670.24 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $559.56 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $418.07 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $301.66 | 2021-2025 | |
| Scpharmaceuticals INC. | $258.55 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.85 | 2022-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $197.85 | 2024 | Arcalyst |
| Biotronik Nro, INC. | $185.63 | 2025 | Prospera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.42 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $154.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.92 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Azurity Pharmaceuticals, INC. | $137.06 | 2023-2024 | Edarbyclor, Edarbyclor, Edarbi |
| Corcept Therapeutics | $119.43 | 2024-2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $102.14 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $99.33 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.10 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $74.16 | 2025 | Onpattro |
| Heartflow, INC. | $73.28 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.70 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $47.61 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $40.81 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $39.08 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $35.81 | 2025 | Evkeeza |
| Boston Scientific Corporation | $28.62 | 2021-2025 | Watchman Flx |
| Lantheus Medical Imaging, INC. | $27.67 | 2022 | |
| Genzyme Corporation | $16.89 | 2022 | |
| Mannkind Corporation | $15.99 | 2025 | |
| Chiesi USA, INC. | $15.76 | 2025 | Juxtapid |
| Abbott Laboratories | $15.61 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.